Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBITDA Margin (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed EBITDA Margin for 9 consecutive years, with 4423.97% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 4423.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11910.14% through Dec 2025, changed N/A year-over-year, with the annual reading at 721.93% for FY2025, N/A changed from the prior year.
  • EBITDA Margin hit 4423.97% in Q4 2025 for Seres Therapeutics, up from 6403.7% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 53.83% in Q3 2021 to a low of 15436.45% in Q3 2023.
  • Historically, EBITDA Margin has averaged 4289.99% across 4 years, with a median of 2770.61% in 2022.
  • Biggest YoY gain for EBITDA Margin was 707780bps in 2023; the steepest drop was -1369824bps in 2023.
  • Year by year, EBITDA Margin stood at 693.42% in 2021, then tumbled by -916bps to 7045.13% in 2022, then surged by 100bps to 32.67% in 2023, then crashed by -13642bps to 4423.97% in 2025.
  • Business Quant data shows EBITDA Margin for MCRB at 4423.97% in Q4 2025, 6403.7% in Q3 2025, and 32.67% in Q4 2023.